Generic Oncology Drugs Market to Reach US$ 36,029.60 Mn at a CAGR of 6.3% in 2027 | The Insight Partners

Generic Oncology Drugs Market to 2027 - Global Analysis and Forecasts by Molecular Type (Large Molecule, Small Molecule); Indication (Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Kidney Cancer, Cervical Cancer, Others), and Geography

Publication Month: Aug 2019 | Report Code: TIPRE00006393 | No. of Pages: 152 | Category: Pharmaceuticals | Status: Published

The global generic oncology drugs market is expected to reach US$ 36,029.60 Mn in 2027 from US$ 21,200.00 in 2018. The market is estimated to grow with a CAGR of 6.3% from 2019-2027.

The key factors such as increasing prevalence of cancer across the globe, growing generic drug launches and benefits offered by the generic drugs are likely to boost the market growth, whereas, inclination towards the personalized medicine for cancer is likely to be a prevalent trend in the future years. Asia Pacific generic oncology drugs market is expected to grow at highest rate during the forecast period. The growth is contributed by the key driving factors such as development of generics at mass scale, increasing exports by Indian manufacturers, new trade agreements by Asian companies with international players for sales, distribution as well as research collaborations as well as launch of innovative and novel generics for cancer treatment. The market for generic oncology drugs in the Asia Pacific region is expected to reach US$ 7,692.32 Mn in 2027 from US$ 4,299.63 Mn in 2018. The growth rate of the market in the region is estimated to be 6.9% during the forecast period.

 

Exhibit: Lucrative Regional Generic Oncology Drugs Markets

Market Insights

New Drug Launches

The market for generic cancer drugs is driven by frequent drug launches. Most of the major market players are involved in the manufacturing wide range of generic cancer drugs that help in reducing cost of cancer care. For instance, in May 2019, Mylan N.V., a global pharmaceutical company announced the U.S. launch of Erlotinib Hydrochloride Tablets, 25 mg, 100 mg and 150 mg, a generic version of Genentech's Tarceva. Erlotinib Hydrochloride tablets are used for the treatment of patients with metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as identified by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after advancement following at least one earlier chemotherapy. Similarly, in January 2019, Wockhardt received United States Food & Drug Administration (USFDA) approval for 100 mg and 400 mg tablets of Imatinib Mesylate, a generic version of Gleevec, marketed in USA and other countries by Novartis. Thus, the constant developments in generic oncology drugs accelerate the market growth during the forecast period. Thus, the constant developments in generic oncology drugs accelerate the market growth during the forecast period.

 

Inclination towards Personalized Medicine

Personalize medicine is a new approach but is a rapidly expanding field in healthcare sector where a medical doctor can select a treatment on the basis of a patient's genetic profile which may not only minimize harmful side effects but also may lead to a successful result in short time.

Cancer personalize medicine involves the study of individuals genetic make up for tumor growth. By studying patient’s genetic make-up, the oncologist may customize the treatment depending on the patient’s genetic mutations. For instance, Mutations in ALK, KRAS and EGFR lead to lung cancer. However, identifying the type of mutation in the lung cancer patient provides crucial information for the type of treatment.  Prior to personalize medicine all patients received the same treatment for a particular type of cancer. However with the advent of personalized medicine, the patient is given treatment on basis of his/her genetic make-up. Patient’s tissue is excised to carry out the genetic diagnosis process. Due to these advantages of tailoring the treatment based on individuals genetic profile, the personalize medicine approach is likely to create many opportunities for the generic oncology drugs market.

 

Molecule Type Insights

The global generic oncology drugs market, based on the molecule type was segmented into small molecule and large molecule. In 2018, the small molecule segment held a largest market share of the generic oncology drugs market, by molecule type. The advantages of small molecules in terms of their complexity and molecular size that can traverse throughout reach to target site and show its effective action as well as advent of personalized drug development are the major factors to likely account for the growth of the segment over the years to come. However, the same segment is expected to witness the highest CAGR of 6.6% over the coming years.

 

Exhibit: Generic Oncology Drugs Market, by Molecule Type

 

Strategic Insights

Product launches, agreements, and acquisitions were observed as the most adopted strategy in the global generic oncology drugs market industry. For instance, in July 2019, Sandoz announced the launch of the generic oncology medicine gefitinib indicated for adult patients with locally advanced or metastatic non-small cell lung cancer with activating mutations of EGFR-TK, which is recommended by ESMO as first-line treatment. Moreover, in September 2016, Glenmark Pharmaceuticals entered into an agreement with US-based Particle Sciences Inc. to develop and market a generic version of Celgene's ABRAXANE which is used in treatments of breast and lung cancers.

 

GLOBAL GENERIC ONCOLOGY DRUGS MARKET – MARKET SEGMENTATION

Global Generic Oncology Drugs Market – By Molecule Type

  • Large Molecule
  • Small Molecule

Global Generic Oncology Drugs Market – By Application

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Kidney Cancer
  • Cervical Cancer
  • Others

Global Generic Oncology Drugs Market – By Region

 

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • France
  • Germany
  • UK
  • Spain
  • Italy
  • Asia Pacific (APAC)
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Middle East & Africa (MEA)
  • Saudi Arabia
  • South Africa
  • UAE
  • South America (SAM)
  • Brazil
  • Argentina

 

Company Profiles

  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GMBH
  • Glenmark
  • Sun Pharmaceutical Industries Ltd
  • MSN Laboratories
  • Aurobindo Pharma
  • Intas Pharmaceuticals
  • Zydus Cadila
  • Mylan N.V.
  • Cipla Inc.
  • Fresenius Kabi AG
  • Dr. Reddy’s Laboratories Ltd

 

 

 

1.             Introduction

1.1       Scope of the Study

1.2       The Insight Partners Research Report Guidance

1.3       Market Segmentation

1.3.1       Global Generic Oncology Drugs Market – By Molecule Type

1.3.2       Global Generic Oncology Drugs Market – By Application

1.3.3       Global Generic Oncology Drugs Market – By Geography

2.             Global Generic Oncology Drugs Market – Key Takeaways

3.             Research Methodology

3.1       Coverage

3.2       Secondary Research

3.3       Primary Research

4.             Global Generic Oncology Drugs– Market Landscape

4.1       Overview

4.2       PEST Analysis

4.2.1       North America PEST Analysis

4.2.2       Europe PEST Analysis

4.2.3       Asia Pacific – PEST Analysis

4.2.4       Middle East & Africa– PEST Analysis

4.2.5       South & Central America – PEST Analysis

4.3       Expert Opinions

5.             Global Generic Oncology Drugs Market – Key Industry Dynamics

5.1       Key Market Drivers

5.1.1       Growing Cancer Prevalence Across The Globe

5.1.2       New Drug Launches

5.1.3       Benefits Offered By Generic Drugs

5.2       Key Market Restraints

5.2.1       Pricing Pressure

5.3       Key Market Opportunities

5.3.1       Growing Pharmaceutical Industry in Emerging Economies

5.4       Future Trends

5.4.1       Inclination Towards Personalized Medicine

5.5       Impact Analysis

6.             Generic Oncology Drugs Market – Global Analysis

6.1       Global Generic Oncology Drugs Market Revenue Forecasts And Analysis

6.2       Global Generic Oncology Drugs Market, By Geography - Forecasts And Analysis

6.3       Market Positioning of Key Players

7.             Generic Oncology Drugs Market Analysis And Forecasts To 2027 – Molecule Type

7.1       Overview

7.2       Global Generic Oncology Drugs Market Share by Molecule Type 2018 & 2027 (%)

7.3       Large Molecules Market

7.3.1       Overview

7.3.2       Large Molecules Market Revenue and Forecast to 2027 (US$ Mn)

7.4       Small Molecules Market

7.4.1       Overview

7.4.2       Small Molecules Market Revenue and Forecast to 2027 (US$ Mn)

8.             Generic Oncology Drugs Market Analysis And Forecasts To 2027 – Indication

8.1       Overview

8.2       Global Generic Oncology Drugs Market Share by Indication 2018 & 2027 (%)

8.3       Lung Cancer

8.3.1       Overview

8.3.2       Lung Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.4       Stomach Cancer

8.4.1       Overview

8.4.2       Stomach Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.5       Colorectal Cancer

8.5.1       Overview

8.5.2       Colorectal Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.6       Breast Cancer

8.6.1       Overview

8.6.2       Breast Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.7       Prostate Cancer

8.7.1       Overview

8.7.2       Prostate Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.8       Liver Cancer

8.8.1       Overview

8.8.2       Liver Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.9       Kidney Cancer

8.9.1       Overview

8.9.2       Kidney Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.10    Cervical Cancer

8.10.1    Overview

8.10.2    Cervical Cancer Market Revenue and Forecast to 2027 (US$ Mn)

8.11    Others

8.11.1    Overview

8.11.2    Others Market Revenue and Forecast to 2027 (US$ Mn)

9.             Generic Oncology Drugs Market Revenue and Forecasts to 2027 – Geographical Analysis

9.1       North America Generic Oncology Drugs Market Revenue And Forecasts To 2027

9.1.1       North America Generic Oncology Drugs market Revenue and Forecasts to 2027 (US$ Mn)

9.2       North America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type  (US$ Mn)

9.3       North America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.3.1       North America Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

9.3.2       US Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.3.2.1    US Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.3.2.2    US Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.3.2.3    US Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.3.3       Canada Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.3.3.1    Canada Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.3.4       Canada Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.3.5       Canada Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.3.6       Mexico Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.3.6.1    Mexico Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.3.7       Mexico Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.3.8       Mexico Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.4       Europe Generic Oncology Drugs Market Revenue And Forecasts To 2027

9.4.1       Europe Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.5       Europe Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.6       Europe Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.6.1       Europe Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

9.6.2       UK Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.2.1    UK Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.3       UK Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.6.4       UK Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.6.5       Germany Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.5.1    Germany Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.6       Germany Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.6.7       Germany Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.6.8       France Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.8.1    France Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.9       France Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.6.10    France Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.6.11    Italy Generic oncology drugs market Revenue and Forecasts to 2027 (US$ Mn)

9.6.11.1  Italy Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.12    Italy Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.6.13    Italy Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

9.6.14    Spain Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.14.1  Spain Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

9.6.15    Spain Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

9.6.16    Spain Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

10.          Asia Pacific Generic Oncology Drugs Market Revenue and Forecasts to 2027

10.1    Overview

10.2    Asia Pacific Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.3    Asia Pacific Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

10.4    Asia Pacific Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

10.5    Asia Pacific Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

10.6    Japan Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.6.1    Japan Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.6.2    Japan Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

10.6.3    Japan Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

10.7    China Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.7.1    China Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.7.2    South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type  (US$ Mn)

10.7.3    China Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

10.8    India Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.8.1    India Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.8.2    India Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

10.8.3    India Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

10.9    Australia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.9.1    Australia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.9.2    Australia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

10.9.3    Australia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

10.10  South Korea Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.10.1 South Korea Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

10.10.2 South Korea Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type  (US$ Mn)

10.10.3 South Korea Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

11.          Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027

11.1    Overview

11.2    Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

11.3    Middle East & Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

11.4    Middle East & Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication  (US$ Mn)

11.5    Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

11.6    South Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

11.6.1    South Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

11.6.2    South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type  (US$ Mn)

11.6.3    South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

11.7    Saudi Arabia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

11.7.1    Saudi Arabia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

11.7.2    Saudi Arabia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type  (US$ Mn)

11.7.3    Saudi Arabia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

11.8    UAE Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

11.8.1    UAE Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

11.8.2    UAE Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

11.8.3    UAE Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

12.          South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027

12.1    Overview

12.2    South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

12.3    South and Central America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

12.4    South and Central America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

12.5    South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027,  By Country (%)

12.6    Brazil Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

12.6.1.1  Brazil Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

12.6.2    Brazil Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

12.6.3    Brazil Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

12.6.4    Argentina Generic Oncology Drugs Market

12.6.4.1  Argentina Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

12.6.5    Argentina Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

12.6.6    Argentina Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

13.          Generic Oncology Drugs Market – Industry Landscape

13.1    Overview

13.2    Growth Strategies in the Generic Oncology Drugs Market, 2016-2019

13.3    Organic Growth Strategies

13.4    Inorganic Growth Strategies

14.          Generic Oncology Drugs Market–Key Company Profiles

14.1    Dr. Reddy’s Laboratories Ltd

14.1.1    Key Facts

14.1.2    Business Description

14.1.3    Financial Overview

14.1.4    Product Portfolio

14.1.5    SWOT Analysis

14.1.6    Key Developments

14.2    Fresenius Kabi AG

14.2.1    Key Facts

14.2.2    Business Description

14.2.3    Financial Overview

14.2.4    Product Portfolio

14.2.5    SWOT Analysis

14.2.6    Key Developments

14.3    Cipla Inc.

14.3.1    Key Facts

14.3.2    Business Description

14.3.3    Financial Overview

14.3.4    Product Portfolio

14.3.5    SWOT Analysis

14.3.6    Key Developments

14.4    Mylan N.V.

14.4.1    Key Facts

14.4.2    Business Description

14.4.3    Financial Overview

14.4.4    Product Portfolio

14.4.5    SWOT Analysis

14.4.6    Key Developments

14.5    Zydus Cadila

14.5.1    Key Facts

14.5.2    Business Description

14.5.3    Financial Overview

14.5.4    Product portfolio

14.5.5    SWOT Analysis

14.5.6    KEY DEVELOPMENTS

14.6    Intas Pharmaceuticals

14.6.1    Key Facts

14.6.2    Business Description

14.6.3    Financial Information

14.6.4    Product Portfolio

14.6.5    SWOT Analysis

14.6.6    Key Developments

14.7    Aurobindo Pharma

14.7.1    Key Facts

14.7.2    Business Description

14.7.3    Financial Overview

14.7.4    Product Portfolio

14.7.5    SWOT Analysis

14.7.6    Key Developments

14.8    Teva Pharmaceutical Industries Ltd.

14.8.1    Key Facts

14.8.2    Business Description

14.8.3    Financial Overview

14.8.4    Product Portfolio

14.8.5    SWOT Analysis

14.8.6    Key Developments

14.9    Sandoz International GmbH (A Division of Novartis AG)

14.9.1    Key Facts

14.9.2    Business Description

14.9.3    Financial Overview

14.9.4    Product Portfolio

14.9.5    SWOT Analysis

14.9.6    Key Developments

14.10  Glenmark

14.10.1 Key Facts

14.10.2 Business Description

14.10.3 Financial Overview

14.10.4 Product Portfolio

14.10.5 SWOT Analysis

14.10.6 Key Developments

14.11  Sun Pharmaceutical Industries Ltd.

14.11.1 Key Facts

14.11.2 Business Description

14.11.3 Financial Overview

14.11.4 Product Portfolio

14.11.5 SWOT Analysis

14.11.6 Key Developments

14.12  MSN Laboratories

14.12.1 Key Facts

14.12.2 Business Description

14.12.3 Financial Overview

14.12.4 Product Portfolio

14.12.5 SWOT Analysis

14.12.6 Key Developments

15.          Appendix

15.1    About The Insight Partners

15.2    Glossary Of Terms


LIST OF TABLES

Table 1.            North America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 2.            North America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 3.            US Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 4.            US Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 5.            Canada Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 6.            Canada Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 7.            Mexico Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 8.            Mexico Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 9.            Europe Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 10.         Europe Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 11.         UK Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 12.         UK Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 13.         Germany Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 14.         Germany Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 15.         France Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 16.         France Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 17.         Italy Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 18.         Italy Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 19.         Spain Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 20.         Spain Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 21.         Asia Pacific Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 22.         Asia Pacific Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 23.         Japan Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 24.         Japan Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 25.         China Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 26.         China Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 27.         India Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 28.         India Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 29.         Australia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 30.         Australia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 31.         South Korea Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 32.         South Korea Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 33.         Middle East & Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type  (US$ Mn)

Table 34.         Middle East & Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 35.         South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 36.         South Africa Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 37.         Saudi Arabia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 38.         Saudi Arabia Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 39.         UAE Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 40.         UAE Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 41.         South and Central America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 42.         South and Central America Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 43.         Brazil Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 44.         Brazil Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 45.         Argentina Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Molecule Type (US$ Mn)

Table 46.         Argentina Generic Oncology Drugs Market Revenue And Forecasts to 2027, By Indication (US$ Mn)

Table 47.         Glossary Of Terms, Generic Oncology Drugs Market

LIST OF FIGURES

Figure 1.          Generic Oncology Drugs Market Segmentation

Figure 2.          Generic Oncology Drugs Segmentation, By Region

Figure 3.          Asia Pacific Generic Oncology Drugs Market, Revenue (US$ Mn), 2018 & 2027

Figure 4.          Global Generic Oncology Drugs Market By Product, Market Share (%), 2018

Figure 5.          Global Generic Oncology Drugs Market By Indication, Market Share (%), 2018

Figure 6.          North America : PEST Analysis

Figure 7.          Europe: PEST Analysis

Figure 8.          Asia Pacific PEST Analysis

Figure 9.          Middle East & Africa PEST Analysis

Figure 10.       South & Central America PEST Analysis

Figure 11.       Most Prevalent Forms of Cancers Globally, 2018

Figure 12.       Comparison of Brand – Name Drugs and Generic Drugs

Figure 13.       Generic Oncology Drugs Market Impact Analysis of Driver And Restraints

Figure 14.       Global Generic Oncology Drugs Market – Revenue Forecasts And Analysis – 2018- 2027

Figure 15.       Global Generic Oncology Drugs Market – By Geography Forecasts And Analysis – 2018- 2027

Figure 16.       Global Generic Oncology Drugs Market – Market Positioning

Figure 17.       Global Generic Oncology Drugs Market Share by Molecule Type 2018 & 2027 (%)

Figure 18.       Large Molecules Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 19.       Small Molecules Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 20.       Global Generic Oncology Drugs Market Share by Indication 2018 & 2027 (%)

Figure 21.       Lung Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 22.       Stomach Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 23.       Colorectal Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 24.       Breast Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 25.       Prostate Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 26.       Liver Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 27.       Kidney Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 28.       Cervical Cancer Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 29.       Others Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 30.       North America Generic Oncology Drugs Market Revenue Overview, by Country, 2018 (US$ Mn)

Figure 31.       North America Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 32.       North America Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

Figure 33.       US Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 34.       Canada Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 35.       Mexico Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 36.       Europe Generic Oncology Drugs Market Revenue Overview, by Country, 2018 (US$ MN)

Figure 37.       Europe Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 38.       Europe Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

Figure 39.       UK Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 40.       Germany Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 41.       France Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 42.       Italy Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 43.       Spain Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 44.       Asia Pacific Generic Oncology Drugs Market Overview, by Country (2017)

Figure 45.       Asia Pacific Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 46.       Asia Pacific Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

Figure 47.       Japan Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 48.       China Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 49.       India Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 50.       Australia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 51.       South Korea Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 52.       Middle East & Africa Generic Oncology Drugs Market Overview, by Country (2017)

Figure 53.       Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 54.       Middle East & Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

Figure 55.       South Africa Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 56.       Saudi Arabia Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 57.       UAE Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 58.       South and Central America Generic Oncology Drugs Market Overview, by Country (2017)

Figure 59.       South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027 (US$ Mn)

Figure 60.       South and Central America Generic Oncology Drugs Market Revenue and Forecasts to 2027, By Country (%)

Figure 61.       Brazil Generic Oncology Drugs Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 62.       Argentina Generic Oncology Drugs Market Revenue And Forecasts To 2027 (US$ Mn)

Figure 63.       Growth Strategies in the Generic Oncology Drugs Market, 2016-2019

The List of Companies

  1. Teva Pharmaceutical Industries Ltd.
  2. Sandoz International GMBH
  3. Glenmark
  4. Sun Pharmaceutical Industries Ltd
  5. MSN Laboratories
  6. Aurobindo Pharma
  7. Intas Pharmaceuticals
  8. Zydus Cadila
  9. Mylan N.V.
  10. Cipla Inc.
  11. Fresenius Kabi AG
  12. Dr. Reddy’s Laboratories Ltd.

 

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the generic oncology drugs market market.

 

  • Highlights key business priorities in order to assist companies to realign their business strategies.

 

  • The key findings and recommendations highlight crucial progressive industry trends in the global generic oncology drugs market market, thereby allowing players across the value chain to develop effective long-term strategies.

 

  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

 

  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.

 

  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.